目的 探討克唑替尼聯(lián)合PC方案治療非小細(xì)胞肺癌的臨床療效。方法 選擇2016年1月—2018年12月新疆喀什地區(qū)第二人民醫(yī)院治療的64例非小細(xì)胞肺癌患者作為研究對(duì)象。用抽簽法隨機(jī)將患者分為對(duì)照組和觀察組，每組各32例。對(duì)照組每天靜脈滴入注射用培美曲塞二鈉，500 mg/m²，靜滴時(shí)間超過(guò)10 min，并靜脈滴入卡鉑注射液，AUC5靜滴時(shí)間超過(guò)30 min。觀察組在對(duì)照組的基礎(chǔ)上口服克唑替尼膠囊，250 mg/次，2次/d。1個(gè)周期為21 d，兩組共治療2個(gè)周期。觀察兩組患者的臨床療效，同時(shí)比較兩組患者治療前后的血清癌胚抗原（CEA）、神經(jīng)元特異性烯醇化酶（NSE）、人鱗狀細(xì)胞癌相關(guān)抗原（SCCAg）以及細(xì)胞角蛋白19片段（Cyfra21-1）水平和Karnofsky功能狀態(tài)評(píng)分量表（KPS）評(píng)分情況。結(jié)果 治療后，觀察組總有效率為81.25%，明顯高于對(duì)照組的59.37%（P<0.05）。兩組治療后的NSE、CEA、SCCAg和CYFRA21-1水平均明顯降低（P<0.05），且觀察組上述腫瘤標(biāo)志物水平明顯低于對(duì)照組（P<0.05）。治療后，觀察組的生活質(zhì)量好轉(zhuǎn)率明顯高于對(duì)照組，惡化率明顯低于對(duì)照組（P<0.05）。結(jié)論 克唑替尼聯(lián)合PC方案治療非小細(xì)胞肺癌患者的療效顯著，能明顯降低腫瘤標(biāo)志物水平，提高生活質(zhì)量。

Objective To investigate the clinical efficacy of crizotinib combined with PC regimen in treatment of non-small cell lung cancer. Methods A total of 64 patients with non-small cell lung cancer treated in The Second People's Hospital of Kashgar Region from January 2016 to December 2018 were selected as study subjects. Patients were randomly divided into control group and observation group with 32 patients in each group by lottery. Patients in the control group were iv administered with Pemetrexed Disodium for Injection for more than 10 min, 500 mg/m², and iv administered with AUC5 Carboplatin Injection more than 30 min. Patients in the observation group were po administered with Crizotinib Capsules on the basis of control group, 250 mg/time, twice daily. One cycle was 21 days, and the two groups were treated for 2 cycles. After treatment, the clinical efficacy in two groups was observed, and the serum levels of CEA, NSE, SCCAg, Cyfra21-1, and KPS scores before and after treatment in the two groups were compared. Results After treatment, the total effective rate of the observation group was 81.25%, which was significantly higher than 59.37% of the control group (P<0.05). After treatment, the levels of NSE, CEA, SCCAg, and CYFRA21-1 in two groups were significantly decreased (P<0.05), and the levels of tumor markers in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the improvement rate of quality of life in the observation group was significantly higher than that in the control group, and the deterioration rate was significantly lower than that in the control group (P<0.05). Conclusion Crizotinib combined with PC regimen in treatment of non-small cell lung cancer has a significant effect, which can significantly reduce the level of tumor markers, improve the quality of life.

R974

新疆維吾爾自治區(qū)自然科學(xué)基金資助項(xiàng)目（2016D01C091）